An Open-Label, Randomized, Partially Fixed-Sequence, 4-Period Crossover Study to Assess the Pharmacokinetics After Administration of the DFC and OCT Formulations and the Food Effect on the OCT Formulation of MK-0941 in Patients With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 17 Sep 2012
At a glance
- Drugs MK 0941 (Primary) ; MK 0941
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 05 Jan 2012 Actual end date changed from Mar 2008 to Apr 2008 as reported by ClinicalTrials.gov.
- 08 May 2008 Status change from recruiting to completed, according to clinicaltrials.gov.
- 07 Jan 2008 Status changed from initiated to recruiting.